Clinical Trial Update: Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating low-dose or high-dose lenalidomide in children with NF1-associated recurrent pilocytic astrocytoma or optic pathway glioma. The study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Optic Pathway Glioma
• Pilocytic Astrocytoma

Drugs mentioned

• Lenalidomide (lenalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neurofibromatosis Type 1, Recurrent Childhood Pilocytic Astrocytoma | Phase 2 | Status: COMPLETED | Results posted: 2021-11-30